BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10581162)

  • 1. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.
    Cohen HT; Zhou M; Welsh AM; Zarghamee S; Scholz H; Mukhopadhyay D; Kishida T; Zbar B; Knebelmann B; Sukhatme VP
    Biochem Biophys Res Commun; 1999 Dec; 266(1):43-50. PubMed ID: 10581162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
    Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
    Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta.
    Pal S; Claffey KP; Cohen HT; Mukhopadhyay D
    J Biol Chem; 1998 Oct; 273(41):26277-80. PubMed ID: 9756852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.
    Zatyka M; Morrissey C; Kuzmin I; Lerman MI; Latif F; Richards FM; Maher ER
    J Med Genet; 2002 Jul; 39(7):463-72. PubMed ID: 12114475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter.
    Rafty LA; Khachigian LM
    J Cell Biochem; 2002; 85(3):490-5. PubMed ID: 11967988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
    Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
    Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
    Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
    Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
    Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
    EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
    Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
    Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targeting of VHL gene pathway in clear cell kidney cancer.
    Linehan WM
    J Urol; 2003 Aug; 170(2 Pt 1):593-4. PubMed ID: 12853837
    [No Abstract]   [Full Text] [Related]  

  • 15. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
    Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
    Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
    Pal S; Claffey KP; Dvorak HF; Mukhopadhyay D
    J Biol Chem; 1997 Oct; 272(44):27509-12. PubMed ID: 9346879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
    Brieger J; Weidt EJ; Schirmacher P; Störkel S; Huber C; Decker HJ
    J Mol Med (Berl); 1999 Jun; 77(6):505-10. PubMed ID: 10475065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
    Gnarra JR; Zhou S; Merrill MJ; Wagner JR; Krumm A; Papavassiliou E; Oldfield EH; Klausner RD; Linehan WM
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10589-94. PubMed ID: 8855222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.